Portside Wealth Group LLC Purchases New Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Portside Wealth Group LLC acquired a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,352 shares of the medical instruments supplier’s stock, valued at approximately $497,000.

Several other institutional investors also recently modified their holdings of the company. NBC Securities Inc. lifted its position in LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the period. GAMMA Investing LLC lifted its holdings in shares of LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 199 shares during the period. USA Financial Formulas acquired a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at about $60,000. West Oak Capital LLC bought a new stake in LeMaitre Vascular in the second quarter valued at about $58,000. Finally, nVerses Capital LLC raised its position in LeMaitre Vascular by 33.3% in the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 3.1 %

Shares of NASDAQ LMAT opened at $104.25 on Friday. LeMaitre Vascular, Inc. has a 12-month low of $47.72 and a 12-month high of $104.81. The firm’s 50-day simple moving average is $90.66 and its 200 day simple moving average is $84.27. The company has a market cap of $2.34 billion, a price-to-earnings ratio of 56.97, a price-to-earnings-growth ratio of 2.49 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular’s quarterly revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.33 earnings per share. On average, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be given a dividend of $0.16 per share. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.61%. LeMaitre Vascular’s payout ratio is currently 34.97%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on LMAT shares. Barrington Research lifted their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Wednesday. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock. Finally, JMP Securities upped their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $94.57.

Insider Activity

In related news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.